News

New facilities are expected to focus on manufacturing next-generation medicines and biologic medicines.

The company—whose foundation has committed $1.5 million for in donations for recovery—is currently working on a plan that will help limit supply disruption.

In the final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, predicts how the future of data accessibility will unfold.

Are these statistical characteristics—along with social determinants of health—associated with denials of preventive care claims?

In the third part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, details the importance of E2E visibility.

In the second part of his interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, explains the sales and operations planning (SO&P) process that can help create logistical efficiencies.

The session details how these teachings span the entire pharma supply chain.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Gautam Prem Jain, GoComet’s Co-founder and CEO, discusses obstacles encountered by shippers in the pharmaceutical sector.

The provider’s partnership with AI innovator Odaia offers deeper, broader insights to HCP activity.

A panel offers its perspective on bolstering the temperature monitoring and data sharing process.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Arnon Lopes, head, customer experience, pharma & healthcare, JAS, discusses ways that IoT can support sustainable supply chains at LogiPharma USA in Boston.

A panel offers insight surrounding the industry’s carbon footprint, including ways to begin initiating positive change.

Session discusses the soft skills needed to ensure that communication strategies are being followed with distributors and other logistical partners across the value chain.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Mark Karhoff, supply chain & DSCSA consultant, National Association of Boards of Pharmacy, discusses the NABP's PULSE program and how it will support supply chains.

With the Nov. 27 deadline fast approaching, is the pharma supply chain ready for full data exchange?

In an interview with Pharma Commerce Editor Nicholas Saraceno, Mark Karhoff, supply chain & DSCSA consultant, National Association of Boards of Pharmacy, discusses insurances to the upcoming DSCSA deadline.

Bimzelx is the first approved medication for active psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis that selectively inhibits IL-17A and IL-17F, both of which are key cytokines that drive inflammatory processes.

In a final part of his interview with Pharma Commerce Editor Nicholas Saraceno, Kevin MacDonald, Bluesight’s Co-founder and CEO, explains the amount of time it takes to see a reduction in annualized drug spend, and offers estimates in terms of percent savings.

A study examines if this PCP-large health system dynamic impacts patient outcomes.

Results of the Phase III CENTERSTONE study demonstrated that when Xofluza is taken by an individual with influenza, it lowers the risk of others in the household contracting it.

The collaboration is centered around meeting track-and-trace requirements.

Despite support from patient assistance programs and legislation designed to combat growing healthcare costs, challenges remain.

Accord BioPharma's 420 mg strength Hercessi (trastuzumab-strf), a biosimilar to Herceptin, gains FDA approval to treat HER2-overexpressing breast cancer and gastric cancer.

Drug shortages, including critical antibiotics, fever medications, and cancer treatments, highlight global supply chain issues and the need for improved health policies to prevent medication bottlenecks.

FDA fast tracks Sun Pharma and Moebius Medical’s MM-II treatment for osteoarthritis knee pain, with Phase III clinical trials planned to expedite a potential approval.

The manufacturing line producing the company’s branded form of nirsevimab-alip has been approved by the FDA.

It’s essential for commercial success, but presents its share of obstacles.

A study aims to determine whether there are disparities in burden and treatment across neighborhoods, and if socioeconomic position, race, ethnicity have an impact.

A cross-sectional study investigates changes in Medicare Advantage enrollment among Medicare beneficiaries with end-stage renal disease in the first two years of the Act.

In the final part of her interview with Pharma Commerce Editor Nicholas Saraceno, Elizabeth A. Gallenagh, General Counsel and Senior Vice President, Supply Chain Integrity, Healthcare Distribution Alliance, discusses the WEE request process itself, while also providing her thoughts on other sessions that have garnered her attention.